Rose McNulty

Delivering patient-centered care in the community oncology setting is a multifaceted endeavor, requiring buy-in not only from providers and practices but also from payers and other stakeholders impacting providers’ ability to deliver high-quality care. Collaboration between providers and payers was […]

Cancer care is constantly evolving, with treatment armamentariums expanding and new data releases coming at an increasing pace. Still, novel therapies are not without their challenges, and questions related to the costs, outcomes, and patient quality-of-life improvements associated with emerging

Continuing our conversation with Ticiana Leal, MD, here she explains the importance of biomarker testing in the perioperative setting for patients who have early-stage non–small cell lung cancer (NSCLC), and how and why conversations across disciplines and during tumor boards

HDP-101, a novel investigational B-cell maturation antigen (BCMA)–targeting antibody-drug conjugate (ADC), demonstrated encouraging efficacy in patients with progressive or refractory multiple myeloma in the phase 1/2a HDP-101-01 trial (NCT04879043). Updated results from the first-in-human, open-label, non-randomized, multicenter study were presented

In the phase 2 FORWARD-53 study (NCT04906460), the investigational exon-skipping oligonucleotide WVE-N531 has shown promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping, according to an interim analysis of the trial. The

Two quadruplet regimens for transplant-eligible newly diagnosed multiple myeloma (NDMM)—daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) and daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd)—showed deep, durable responses in data presented at the 21st International Myeloma Society Annual Meeting & Exposition,